Gracell Biotechnologies, a Nasdaq-listed Chinese biopharmaceutical firm that develops cell therapies targeting cancer and autoimmune diseases, has inked a deal to raise $150 million in a private placement from a group of healthcare specialist funds.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
